Effect of l-carnitine supplementation on liver fat content and cardiometabolic indices in overweight/obese women with polycystic ovary syndrome: A randomized controlled trial

Sangouni, Abbas Ali; Sasanfar, Bahareh; Ghadiri‐Anari, Akram; Hosseinzadeh, Mahdieh

doi:10.1016/j.clnesp.2021.08.005

Cited by 9 publications

(11 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We demonstrated that AIP, AC and CRI-II did not change after 12-week L-carnitine supplementation. Consistent with our findings, a RCT showed that L-carnitine supplementation (1000 mg/day) for 12 weeks could not improve AIP, AC and CRI-II in patients with PCOS [ 28 ]. AIP, AC and CRI-II are based on lipid profile [ 10 , 33 , 34 ].…”

Section: Discussionsupporting

confidence: 90%

“…A RCT evaluated the effect of 12-week L-carnitine supplementation (1000 mg/day) on LAP, and reported that L-carnitine has no effect on LAP among women with PCOS [ 28 ]. The crude results of our study was similar to the study of Sangouni et al [ 28 ]; however, we found a significant reduction of LAP after adjusting for education of participants. WC and TG are used in the equation of LAP [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

“…The studies that evaluated the effect of L-carnitine in patients with osteoarthritis are scarce [ 19 , 26 , 27 ]. In addition, only one study examined the effect of L-carnitine supplementation on LAP and atherogenic indices in women with polycystic ovary syndrome (PCOS) [ 28 ]. Therefore, we designed a clinical trial to investigate the effect of L-carnitine supplementation on LAP and cardiovascular indices in women with overweight/obesity who have knee osteoarthritis.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of L-carnitine supplementation on lipid accumulation product and cardiovascular indices in women with overweight/obesity who have knee osteoarthritis: a randomized controlled trial

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background Osteoarthritis is associated with obesity, dyslipidemia and cardiovascular diseases. It has been hypothesized that L-carnitine can improve cardiovascular risk factors. We aimed to investigate the effect of L-carnitine supplementation on lipid accumulation product (LAP) and atherogenic indices in women with overweight/obesity who have knee osteoarthritis. Methods In this double-blind randomized controlled trial, seventy-six women with overweight/obesity who had knee osteoarthritis were assigned into the intervention group and control group for 12 weeks. The intervention group received 1000 mg/day L-carnitine as capsule, and the control group received placebo. The primary outcomes were LAP, atherogenic index of plasma (AIP), atherogenic coefficient (AC) and Castelli risk index II (CRI-II). Results We found no significant difference between the groups in baseline values of LAP, AIP, AC and CRI-II. After the intervention, a significant reduction in LAP was observed in intervention group compared to the control group (− 11.05 (− 28.24 to 0.40) vs. − 5.82 (− 24.44 to 2.68); P = 0.03). However, there was no significant difference between two groups in AIP (− 0.05 ± 0.16 vs. − 0.01 ± 0.13; P = 0.19), AC (− 0.40 ± 0.81 vs. − 0.30 ± 0.67; P = 0.67) and CRI-II (− 0.20 ± 0.76 vs. − 0.21 ± 0.47; P = 0.11). Conclusions L-carnitine supplementation for 12 weeks can improve LAP, but it has no effect on cardiovascular outcomes. To reach a definitive conclusion, further clinical trials with larger sample sizes and higher dosages of L-carnitine are needed. Trial registration Registered on 27/4/2017 at Iranian Registry of Clinical Trials IRCT2017011932026N2.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of L-carnitine supplementation on lipid accumulation product and cardiovascular indices in women with overweight/obesity who have knee osteoarthritis: a randomized controlled trial

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…After retrieving the remaining 22 articles, the full texts of each one was carefully reviewed to determine their eligibility. The following four causes led to the exclusion of a 14 further articles: two publications were conference abstracts [ 37 , 38 ]; two of the publications were posters [ 39 , 40 ]; one study involved patients with polycystic ovarian syndrome [ 41 ]; one study enrolled patients under the age of 18 [ 42 ]; one study involved no imagistic or histopathological confirmation of hepatic steatosis [ 43 ]; and seven publications were interventional studies [ 44 , 45 , 46 , 47 , 48 , 49 , 50 ]. Eight publications in total [ 4 , 5 , 51 , 52 , 53 , 54 , 55 , 56 ] were included in the systematic review, and six of these [ 4 , 5 , 51 , 52 , 55 , 56 ] were also included in the meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

(1) Background: Approximately a billion people worldwide are affected by NAFLD, which places a high clinical burden and financial cost on society. Liver biopsy is the gold standard for diagnosing NAFLD, but its invasivity limits the early diagnosis of NAFLD. Hence, it is important to look for alternate techniques in detecting and diagnosing NAFLD. NAFLD is associated with atherosclerosis. The purpose of this study was to assess the effectiveness of the atherogenic index of plasma (AIP) as a non-invasive modality for predicting NAFLD. (2) Methods: A search using electronic databases PubMed, EMBASE, and Scopus was carried out to find observational studies, looking at research that had been published up until the date of 11 May 2022. The included studies’ quality, risk of bias, and internal validity were evaluated using the QUADAS-2 quality assessment tool. The key summary outcomes were the mean difference (MD) and area under the curve (AUC). (3) Results: A total of eight studies (81,178 participants) were included in our review, while 17% of the included participants had NAFLD. A sex distribution of 57.8% men and 42.2% women was observed. The AIP between NAFLD and the controls was not significant (MD 0.212 [95% CI 0.231–0.655]). A significant MD in AIP between the males and females with NAFLD was observed (MD 0.246 [95% CI 0.098–0.395]). The AIP predicted NAFLD with an AUC of 0.764 as well as in males (AUC 0.761) and females (AUC 0.733). (4) Conclusions: There was a substantial MD in the AIP between both sexes, but there was no significant difference in the AIP values between patients with NAFLD and the controls. The AIP is a reliable biomarker for the diagnosis of NAFLD since its ability to predict the development of NAFLD was comparable to that of the other biomarkers.

show abstract

“…Insulin resistance, inflammation, dyslipidemia, oxidative stress and obesity are involved in the pathogenesis of both T2DM and NAFLD [ 6 – 8 ]. Recently, new non-invasive indices including lipid accumulation product (LAP) and visceral adiposity index (VAI) have been introduced [ 9 , 10 ] that can accurately assess hepatic steatosis [ 9 – 13 ]. It is also well established that prevalence of CVD is high among patients with T2DM, and it is known as a main cause of death among patients with T2DM [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial

Mozaffari‐Khosravi

2022

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background Patients with type 2 diabetes mellitus (T2DM) are prone to develop non-alcoholic fatty liver disease (NAFLD) and cardiovascular diseases (CVD). We aimed to investigate whether the resveratrol supplementation improves novel hepatic and cardiovascular indices in these patients. Methods We conducted a double-blind, randomized controlled trial for 8 weeks. Seventy-six patients with T2DM were randomly assigned to receive 1000 mg/day resveratrol or placebo. Levels of lipid accumulation product (LAP), visceral adiposity index (VAI), Castelli risk index I (CRI-I), CRI-II and atherogenic coefficient (AC) were measured at the beginning and after intervention. Results A total of 71 participants completed the trial. After adjusting for confounding factors including medications, diabetes duration, energy intake and physical activity, no significant difference was found between the intervention group and the control group in LAP (mean change: − 2.46 ± 23.3 vs. 1.43 ± 14.3; P = 0.43), VAI (mean change: − 0.25 ± 1.1 vs. − 0.02 ± 0.6; P = 0.47), CRI-I (mean change: − 0.25 ± 0.9 vs. − 0.09 ± 0.5; P = 0.79), CRI-II (mean change: − 0.23 ± 0.7 vs. − 0.06 ± 0.6; P = 0.38) and AC (mean change: − 0.25 ± 0.9 vs. − 0.09 ± 0.5; P = 0.79). Conclusions Resveratrol supplementation had no effect on hepatic steatosis and cardiovascular indices. Further clinical trials, especially among subjects with dyslipidemia are needed to reach a firm conclusion. In addition, taking all medications should be controlled in future studies. Trial registration The protocol was registered on 29/12/2017 at the Iranian clinical trials website (IRCT20171118037528N1) with URL: https://en.irct.ir/trial/27734.

show abstract

Effect of l-carnitine supplementation on liver fat content and cardiometabolic indices in overweight/obese women with polycystic ovary syndrome: A randomized controlled trial

Cited by 9 publications

References 48 publications

Effect of L-carnitine supplementation on lipid accumulation product and cardiovascular indices in women with overweight/obesity who have knee osteoarthritis: a randomized controlled trial

Effect of L-carnitine supplementation on lipid accumulation product and cardiovascular indices in women with overweight/obesity who have knee osteoarthritis: a randomized controlled trial

Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis

Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial

Contact Info

Product

Resources

About